((自动化翻译由路透提供,请见免责声明 ))
11月8日 - ** 阿斯利康 股价上涨1.8%,报9900便士,是富时100 指数中涨幅最大的公司之一
** 在针对慢性鼻炎伴鼻息肉患者的WAYPOINT III期试验中,制药公司的哮喘药物Tezspire达到了 (link)。
** Tezspire能显著减少鼻息肉的大小和鼻塞程度
** 试验中Tezspire的安全性和耐受性与其已知情况一致
** AZN 年度跌幅约为 6
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.